文献速递肿瘤 PET/CT甲状腺核医学

18F-DOPA PET/CT与68Ga-DOTANOC PET/CT作为局灶性先天性高胰岛素血症诊断工具的盲法评估

18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-11-08

该回顾性研究纳入2005年8月至2016年6月在欧登塞大学医院就诊的55例先天性高胰岛素血症(CHI)患儿,盲法评估18F-DOPA PET/CT与68Ga-DOTANOC PET/CT对局灶性CHI的预测价值,以胰腺组织学或基因结果为金标准。结果显示18F-DOPA PET/CT预测局灶性CHI的敏感度为1(0.85-1)、特异度为0.96(0.82-0.99),其曲线下面积0.98(0.93-1)优于68Ga-DOTANOC PET的0.71(0.43-0.95)(p < 0.03)。作者结论认为18F-DOPA PET/CT预测局灶性CHI表现优异且优于68Ga-DOTANOC PET/CT,不鼓励继续使用68Ga-DOTANOC PET/CT预测局灶性CHI。

要点

  • 18F-DOPA PET/CT预测局灶性CHI的敏感度为1(0.85-1),特异度为0.96(0.82-0.99)。
  • 18F-DOPA PET的SUVmax比值最佳截断值为1.44,68Ga-DOTANOC PET的SUVmax最佳截断值为6.77 g/ml。
  • 18F-DOPA PET曲线下面积0.98(0.93-1)优于68Ga-DOTANOC PET的0.71(0.43-0.95)(p < 0.03)。

核心结论

  • 18F-DOPA PET/CT在预测局灶性CHI方面表现优异,且优于68Ga-DOTANOC PET/CT。
  • 作者不鼓励继续使用68Ga-DOTANOC PET/CT预测局灶性CHI。

研究设计与样本

  • 回顾性评估2005年8月至2016年6月期间在欧登塞大学医院就诊的CHI患儿的PET/CT扫描。
  • 55例CHI患儿接受PET/CT检查(18F-DOPA n = 53,68Ga-DOTANOC n = 18)。
  • 由两名独立检查者盲法进行视觉评估和最大标准化摄取值(SUVmax)评估,盲于临床、手术和病理数据。
  • 以胰腺组织学作为金标准;未手术患者以基因结果作为金标准。
  • 34例患者接受手术,21例未接受手术。

主要发现

  • 18F-DOPA PET/CT通过视觉评估和截断值评估识别局灶性CHI的预测性能相同:敏感度1(0.85-1),特异度0.96(0.82-0.99)。
  • 18F-DOPA PET的SUVmax比值最佳截断值为1.44,68Ga-DOTANOC PET的SUVmax最佳截断值为6.77 g/ml。
  • 受试者工作特征曲线下面积:18F-DOPA PET为0.98(0.93-1),68Ga-DOTANOC PET为0.71(0.43-0.95)(p < 0.03)。
  • 在接受手术的患者中,18F-DOPA PET/CT和68Ga-DOTANOC PET/CT定位局灶性病变的正确率分别为91%和100%。

关键数值与推荐

  • 18F-DOPA PET/CT预测局灶性CHI的敏感度为1(0.85-1),特异度为0.96(0.82-0.99)。
  • 18F-DOPA PET的SUVmax比值最佳截断值为1.44。
  • 68Ga-DOTANOC PET的SUVmax最佳截断值为6.77 g/ml。
  • 18F-DOPA PET的曲线下面积为0.98(0.93-1),68Ga-DOTANOC PET为0.71(0.43-0.95)(p < 0.03)。
  • 手术患者中18F-DOPA PET/CT定位正确率为91%,68Ga-DOTANOC PET/CT为100%。

临床怎么用

  • 原文结论认为18F-DOPA PET/CT在预测局灶性CHI方面表现优异且优于68Ga-DOTANOC PET/CT。
  • 作者不鼓励继续使用68Ga-DOTANOC PET/CT预测局灶性CHI。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Focal congenital hyperinsulinism (CHI) is curable by surgery, which is why identification of the focal lesion is crucial. We aimed to determine the use of 18F-fluoro-dihydroxyphenylalanine (18F-DOPA) PET/CT vs. 68Ga-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic-acid-1-Nal3-octreotide (68Ga-DOTANOC) PET/CT as diagnostic tools in focal CHI. METHODS: PET/CT scans of children with CHI admitted to Odense University Hospital between August 2005 and June 2016 were retrospectively evaluated visually and by their maximal standardized uptake values (SUVmax) by two independent examiners, blinded for clinical, surgical and pathological data. Pancreatic histology was used as the gold standard. For patients without surgery, the genetic profile served as the gold standard. RESULTS: Fifty-five CHI patients were examined by PET/CT (18F-DOPA n = 53, 68Ga-DOTANOC n = 18). Surgery was performed in 34 patients, no surgery in 21 patients. Fifty-one patients had a classifiable outcome, either by histology (n = 33, 22 focal lesions, 11 non-focal) or by genetics (n = 18, all non-focal). The predictive performance of 18F-DOPA PET/CT to identify focal CHI was identical by visual- and cut-off-based evaluation: sensitivity (95% CI) of 1 (0.85-1); specificity of 0.96 (0.82-0.99). The optimal 18F-DOPA PET SUVmax ratio cut-off was 1.44 and the optimal 68Ga-DOTANOC PET SUVmax cut-off was 6.77 g/ml. The area under the receiver operating curve was 0.98 (0.93-1) for 18F-DOPA PET vs. 0.71 (0.43-0.95) for 68Ga-DOTANOC PET (p < 0.03). In patients subjected to surgery, localization of the focal lesion was correct in 91%, and 100%, by 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT, respectively. CONCLUSION: 18F-DOPA PET/CT was excellent in predicting focal CHI and superior compared to 68Ga-DOTANOC PET/CT. Further use of 68GA-DOTANOC PET/CT in predicting focal CHI is discouraged.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Christiansen CD, Petersen H, Nielsen AL, et al. 18F-DOPA PET/CT and 68Ga-DOTANOC PET/CT scans as diagnostic tools in focal congenital hyperinsulinism: a blinded evaluation. Eur J Nucl Med Mol Imaging. 2017. PMID: 29116340. doi:10.1007/s00259-017-3867-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。